ライフサイエンスコーパス: arterial disease

1 (smoking, diabetes mellitus, and peripheral arterial disease).

2 he limbs of certain patients with peripheral arterial disease.

3 ossible matches), 95% of whom had peripheral arterial disease.

4 ts with stable coronary artery or peripheral arterial disease.

5 ypic switching, an important pathobiology in arterial disease.

6 se risks can adversely affect progression of arterial disease.

7 disease and monitoring therapy in peripheral arterial disease.

8 stable coronary artery disease or peripheral arterial disease.

9 en, and patients with diabetes or peripheral arterial disease.

10 e most efficacious treatments for peripheral arterial disease.

11 walking performance developed for peripheral arterial disease.

12 CHD), cerebrovascular disease and peripheral arterial disease.

13 -induced angiogenesis, such as in peripheral arterial disease.

14 on remains unclear in patients with manifest arterial disease.

15 d be extended to patients without peripheral arterial disease.

16 Q can be used in patients without peripheral arterial disease.

17 ith T2D that are related to early markers of arterial disease.

18 s, tobacco use, heart failure, or peripheral arterial disease.

19 d their receptors, adipokines, and miRNAs to arterial disease.

20 ty and mortality in patients with peripheral arterial disease.

21 nt hypertension, preeclampsia, or peripheral arterial disease.

22 pathy, ischemic heart disease and peripheral arterial disease.

23 age rates in patients with severe peripheral arterial disease.

24 artery of diabetic patients with peripheral arterial disease.

25 validated therapy for symptomatic peripheral arterial disease.

26 A for treatment of infrapopliteal peripheral arterial disease.

27 in patients with symptomatic infrapopliteal arterial disease.

28 sease, heart failure, stroke, and peripheral arterial disease.

29 ase, cerebrovascular disease, and peripheral arterial disease.

30 , coronary revascularisation, and peripheral arterial disease.

31 on is tissue- and life-saving in obstructive arterial disease.

32 unctional decline in persons with peripheral arterial disease.

33 ctional decline among people with peripheral arterial disease.

34 clinical imaging in patients with peripheral arterial disease.

35 art disease, ischaemic stroke, or peripheral arterial disease.

36 carotid dissection, and, rarely, peripheral arterial disease.

37 e in persons with lower-extremity peripheral arterial disease.

38 r than revascularization for lower-extremity arterial disease.

39 ssion worsens vascular outcome in peripheral arterial disease.

40 Mac-1-deficiency did not prevent late graft arterial disease.

41 care of patients with symptomatic peripheral arterial disease.

42 and leukocyte recruitment in lower-extremity arterial disease.

43 impaired in elderly patients with peripheral arterial disease.

44 between [Formula: see text] and subclinical arterial disease.

45 coronary artery disease, and lower extremity arterial disease.

46 d CHD, stroke, heart failure, and peripheral arterial disease.

47 nd surgical revascularization for peripheral arterial disease.

48 hemic heart disease implying a role in human arterial disease.

49 on differences in the location and extent of arterial disease.

50 life-threatening complication of peripheral arterial disease.

51 ons in patients with asymptomatic peripheral arterial disease.

52 increased risks of venous thromboembolic and arterial disease.

53 on of kidney disease, stroke, and peripheral arterial disease.

54 art disease, ischemic stroke, and peripheral arterial disease.

55 ach in patients with advanced below-the-knee arterial disease.

56 ith chronic coronary syndromes or peripheral arterial disease.

57 hemia represents the end stage of peripheral arterial disease.

58 al immunoprivilege or medial inflammation in arterial diseases.

59 articipation of inflammation and immunity in arterial diseases.

60 beneficial against bone demineralization and arterial diseases.

61 CI 0.86-0.98]) and strongest for peripheral arterial disease (1.23 [1.20-1.27]).

62 tion, 1.78 (95% CI 1.53-2.07) for peripheral arterial disease, 1.32 (95% CI 1.15-1.50) for cerebrovas

63 rior stroke/transient ischemic attack, 6.5%; arterial disease, 15.9%; all CHADS-VASc risk factors wer

64 on, of which the most common were peripheral arterial disease (16.2%, n=992) and heart failure (14.1%

65 with stent occlusion or stenoses, peripheral arterial disease (ABI <1.0), symptomatic cardiac disease

66 rongly positively associated with peripheral arterial disease (adjusted cause-specific hazard ratio 2

67 ars old with VTE had 3.3-fold higher risk of arterial disease (adjusted hazard ratio, 3.28; 95% confi

68 es was positively associated with peripheral arterial disease (adjusted HR 2.98 [95% CI 2.76-3.22]),

69 udy examined parenchymal rejection and graft arterial disease after total allomismatched cardiac tran

70 isease mortality and one study on peripheral arterial disease).All but one study reported positive as

71 on second exertion in patients with coronary arterial disease, also known as the warm-up angina pheno

72 m selenium with the prevalence of peripheral arterial disease among 2,062 US men and women 40 years o

73 m and lower limbs is a common consequence of arterial disease and a major source of morbidity and mor

74 values for the pathophysiology of peripheral arterial disease and cancer.

75 terial intima of individuals with peripheral arterial disease and diabetes.

76 s (coronary, cerebrovascular, and peripheral arterial disease and heart failure).

77 cal for blood flow restoration in peripheral arterial disease and is triggered by increasing fluid sh

78 LI) is the most advanced stage of peripheral arterial disease and is usually treated with bypass surg

79 a range of conditions, including peripheral arterial disease and myocardial infarction, where it has

80 disease, the use of paclitaxel in peripheral arterial disease and other conditions, the harm signal n

81 al arterial revascularization for peripheral arterial disease and to assess whether readmission risk

82 as coronary, cerebrovascular, or peripheral arterial disease, and (2) incident heart failure.

83 ADA HbA1c clinical categories for peripheral arterial disease, and 0.683 for ADA fasting glucose conc

84 the absence of beta-blocker use, peripheral arterial disease, and a deeper prosthesis insertion are

85 with preserved ejection fraction, peripheral arterial disease, and abdominal aortic aneurysms, are al

86 disease, cerebrovascular disease, peripheral arterial disease, and all-cause cardiovascular disease,

87 disease, cardiovascular disease, peripheral arterial disease, and all-cause mortality than did fasti

88 med in patients with diabetes and peripheral arterial disease, and at least 25% require subsequent re

89 vessels for diameter, stenosis or occlusion, arterial disease, and central stenosis.

90 including coronary heart disease, peripheral arterial disease, and cerebrovascular disease, in an eld

91 ertension, myocardial infarction, peripheral arterial disease, and impaired renal function were signi

92 , carotid intima-media thickness, peripheral arterial disease, and pulse wave velocity).

93 infections-male sex, hypertension, coronary arterial disease, and serogroup C1 infections-were each

94 risks of coronary heart disease, peripheral arterial disease, and stroke.

95 ed diabetes mellitus, symptomatic peripheral arterial disease, and superficial femoral artery lesions

96 n, previous heart failure, MI, or peripheral arterial disease; and who received coronary artery bypas

97 Heart failure and peripheral arterial disease are the most common initial manifestati

98 the treatment of lower extremity peripheral arterial disease are typified with diminished patency.

99 ne in people with lower extremity peripheral arterial disease are unknown.

100 lae and smooth muscle cells (SMCs), and many arterial diseases are characterized by defective lamella

101 CLI is an advanced form of peripheral arterial disease associated with nonhealing arterial ulc

102 ss (IMT) is a noninvasive marker of systemic arterial disease, associated with atherosclerosis, abnor

103 ary heart disease, heart failure, peripheral arterial disease, asthma, chronic kidney disease, diabet

104 ary heart disease, heart failure, peripheral arterial disease, asthma, chronic kidney disease, diabet

105 s (ie, risk factors, coronary and peripheral arterial disease, asymptomatic carotid stenosis, and 10-

106 ment of patients with symptomatic peripheral arterial disease because they are associated with simila

107 Rates of evaluation for peripheral arterial disease before amputation were low, and testing

108 flow in an experimental model of peripheral arterial disease, by exploiting fluorescence in the NIR-

109 al artery revascularization, lower-extremity arterial disease, carotid endarterectomy or angioplasty,

110 ic medial arterial calcification (MAC) is an arterial disease commonly referred as Monckeberg's scler

111 he fully adjusted odds ratios for peripheral arterial disease comparing selenium quartiles 2, 3, and

112 brovascular, coronary artery, and peripheral arterial diseases) complications.

113 disease, cerebrovascular disease, peripheral arterial disease, congestive heart failure, malignant ve

114 Further they had more peripheral arterial disease, coronary artery disease, carotid steno

115 gous cell therapy for intractable peripheral arterial disease/critical limb ischemia.

116 , and race-adjusted prevalence of peripheral arterial disease decreased with increasing serum seleniu

117 Inflammatory arterial diseases differentially affect the compartments

118 tive imaging approach to evaluate peripheral arterial disease does not exist.

119 c heart disease, aortic aneurysm, peripheral arterial disease, endocarditis, and all other cardiovasc

120 Peripheral arterial disease epidemiology and/or management was repo

121 ase, acute myocardial infarction, peripheral arterial disease, epilepsy, substance abuse, heart failu

122 disease, diabetes mellitus, known peripheral arterial disease, evaluation by a vascular specialist, a

123 7 cerebrovascular disease, and 98 peripheral arterial disease events.

124 d 13 patients suspected of having peripheral arterial disease (five men; mean age, 67 years; age rang

125 sease (coronary artery disease or peripheral arterial disease) followed from 1997 to 2009, AF status

126 ysplasia (FMD) is a rare, nonatherosclerotic arterial disease for which the molecular basis is unknow

127 The SMART score (Second Manifestations of Arterial Disease) for 10-year risk of myocardial infarct

128 Graft arterial disease (GAD) limits long-term solid-organ allo

129 field of cell-based therapies for peripheral arterial disease has been in a state of continuous evolu

130 ease, including HTN, HF, CHD, and peripheral arterial disease, have a better prognosis compared with

131 r stable angina, ischemic stroke, peripheral arterial disease, heart failure, and cardiac arrest, to

132 rs include advanced age, smoking, peripheral arterial disease, high blood pressure, coronary artery d

133 .77; 95% CI, 0.62-0.94; P = .01), peripheral arterial disease (HR, 0.65; 95% CI, 0.49-0.87; P = .004)

134 2), heart failure (HR, 0.84), and peripheral arterial disease (HR, 0.85).

135 s noted for fractures (HR, 1.80), peripheral arterial disease (HR, 2.25), venous thromboembolism (HR,

136 nce interval [CI]: 1.82 to 2.29), peripheral arterial disease (HR: 1.95; 95% CI: 1.72 to 2.21), unher

137 infarction (HR=1.75, P=0.02), and peripheral arterial disease (HR=2.01, P=0.01).

138 disease, coronary artery disease, peripheral arterial disease, hypertension, pulmonary hypertension,

139 l injury and dysfunction precede accelerated arterial disease in allograft vasculopathy and systemic

140 dothelial dysfunction and the progression of arterial disease in the general population is unknown.

141 The age-adjusted prevalence of peripheral arterial disease in the US population has been estimated

142 The age-adjusted prevalence of peripheral arterial disease in the US population was estimated to a

143 epair, bypass for lower extremity peripheral arterial disease - in Ontario, Canada, between 2004 and

144 Surgical treatment options for peripheral arterial disease include angioplasty, endarterectomy, an

145 linical consequences of occlusive peripheral arterial disease include intermittent claudication, that

146 linical consequences of occlusive peripheral arterial disease include pain on walking (claudication),

147 s was previously found to be associated with arterial diseases, including intracranial aneurysm.

148 the Treatment of SFA and Proximal Popliteal Arterial Disease [INPACT SFA I], NCT01175850; IN.PACT Ad

149 ation, cardiac revascularization, peripheral arterial disease intervention, or cardiovascular death.

150 nstay for the treatment of acute and chronic arterial disease involving the coronary and peripheral b

151 Peripheral arterial disease is a manifestation of systemic atherosc

152 Peripheral arterial disease is associated with adverse cardiovascul

153 Peripheral arterial disease is largely considered to be a disease o

154 Because peripheral arterial disease is most commonly caused by atherosclero

155 es, the overall population having peripheral arterial disease is predicted to rise.

156 erventions for lifestyle-limiting peripheral arterial disease is unknown.

157 te coronary syndrome, stroke, and peripheral arterial diseases, is a chronic progressive inflammatory

158 prognosis of myocardial ischemia, peripheral arterial disease, ischemic stroke, etc.

159 ular accident, heart failure, and peripheral arterial disease), kidney disease (a composite of ESKD o

160 quality of life similarly compared to other arterial disease level groups, they underwent revascular

161 In patients with manifest arterial disease, low baseline DBP was associated with m

162 The Secondary Manifestations of ARTerial disease-Magnetic Resonance (SMART-MR) Study is

163 Treatment of peripheral arterial diseases may be distinguished into conservative

164 For peripheral arterial disease, men with PLMI >/=30 compared with the

165 onditions that simulate tumor and peripheral arterial disease microenvironment.

166 to theorize why rates of various subtypes of arterial disease might vary across populations.

167 mouse hindlimb ischemia model of peripheral arterial disease, MITCH-PEG co-delivery of hiPSC-ECs and

168 tive sample size [n(e)] = 9,396); peripheral arterial disease (n(e) = 5,215); abdominal aortic aneury

169 mprehensive Magnetic Resonance of Peripheral Arterial Disease; NCT00587678).

170 -enhanced MR angiography revealed peripheral arterial disease not recognized with duplex US and was m

171 [CI], 0.31-0.45; P=5.5*10(-26)], peripheral arterial disease (odds ratio 0.42; 95% CI, 0.26-0.68; P=

172 lysis revealed that patients with peripheral arterial disease of the lower extremities are at higher

173 ease, cerebrovascular disease, or peripheral arterial disease or with multiple risk factors for ather

174 coronary, cerebrovascular, and/or peripheral arterial) disease or multiple atherothrombotic risk fact

175 (OR, 0.58; 95% CI, 0.43-0.78) and peripheral arterial disease (OR, 0.43; 95% CI, 0.22-0.85) were less

176 se (OR, 0.12; 95% CI, 0.03-0.45), peripheral arterial disease (OR, 6.36; 95% CI, 1.56-25.87), and pro

177 ociations between the CAD-GRS and peripheral arterial disease (OR: 1.28; 95% CI: 1.23 to 1.32), abdom

178 without coronary artery disease, peripheral arterial disease, or diabetes mellitus.

179 patients with renal dysfunction, peripheral arterial disease, or following a brief P2Y12-receptor an

180 with prior myocardial infarction, peripheral arterial disease, or stroke.

181 nts with diabetes, heart failure, peripheral arterial disease, or tobacco use had the largest predict

182 ated with progression of preclinical carotid arterial disease over a 6-year period and was more close

183 cluding among individuals without peripheral arterial disease (P<0.001).

184 Peripheral arterial disease (PAD) affects 5 million people in the U

185 rs explain the high prevalence of peripheral arterial disease (PAD) among African Americans.

186 respond poorly to treatments for peripheral arterial disease (PAD) and are more likely to present wi

187 nic arsenic exposure is linked to peripheral arterial disease (PAD) and cardiovascular disease.

188 differences in the prevalence of peripheral arterial disease (PAD) and its associations with cardiov

189 Peripheral arterial disease (PAD) and osteoporosis are chronic illn

190 The ABI is used to diagnose peripheral arterial disease (PAD) and to identify those at risk for

191 ulate angiogenesis are altered in peripheral arterial disease (PAD) and whether these factors are ass

192 Patients with peripheral arterial disease (PAD) are at a high risk for cardiovasc

193 Patients with peripheral arterial disease (PAD) are at increased risk of cardiova

194 nvestigate the pathophysiology of peripheral arterial disease (PAD) by examining magnetic resonance i

195 Peripheral arterial disease (PAD) caused by occlusive atheroscleros

196 Peripheral arterial disease (PAD) causes significant morbidity and

197 dial infarction (MI), stroke, and peripheral arterial disease (PAD) during the subsequent 8 yr.

198 rtance: Patients with concomitant peripheral arterial disease (PAD) experience worse cardiovascular o

199 Patients with peripheral arterial disease (PAD) have high rates of adverse cardio

200 en and women with lower extremity peripheral arterial disease (PAD) have higher levels of inflammator

201 Patients with peripheral arterial disease (PAD) have increased risk on future cer

202 her prevalence of lower-extremity peripheral arterial disease (PAD) in black adults.

203 Cadmium has been associated with peripheral arterial disease (PAD) in cross-sectional studies, but p

204 edside tests for the detection of peripheral arterial disease (PAD) in diabetes.

205 ; weight (kg)/height (m)(2)) with peripheral arterial disease (PAD) in prior studies may reflect lowe

206 chronic kidney disease (CKD), and peripheral arterial disease (PAD) in the general population.

207 Peripheral arterial disease (PAD) is a clinical condition caused by

208 Peripheral arterial disease (PAD) is a clinical manifestation of ex

209 Peripheral arterial disease (PAD) is a costly source of morbidity a

210 Peripheral arterial disease (PAD) is a subclinical measure of ather

211 Peripheral arterial disease (PAD) is an important cardiovascular di

212 Peripheral arterial disease (PAD) is caused by atherosclerosis that

213 The prevalence of peripheral arterial disease (PAD) is increasing worldwide, with rec

214 PURPOSE OF REVIEW: Peripheral arterial disease (PAD) is underdiagnosed, undertreated,

215 mmation in the pathophysiology of peripheral arterial disease (PAD) is well established, the contribu

216 antageous approach to symptomatic peripheral arterial disease (PAD) over the longer term.

217 an important role in determining peripheral arterial disease (PAD) pathology, which causes a spectru

218 0.1, mean age 30 +/- 7 years); 2) peripheral arterial disease (PAD) patients (n = 12; mean ABI 0.6 +/

219 emius biopsies from patients with peripheral arterial disease (PAD) predict mortality rates.

220 Genetic determinants of peripheral arterial disease (PAD) remain largely unknown.

221 amputation risk in patients with peripheral arterial disease (PAD) remains difficult.

222 ntially increases the severity of peripheral arterial disease (PAD) symptomology, however, the biolog

223 Peripheral arterial disease (PAD) was defined by ankle brachial ind

224 urine cadmium concentrations with peripheral arterial disease (PAD) were evaluated by using data from

225 tion of progressive versus stable peripheral arterial disease (PAD) with the risk of future cardiovas

226 rength training for patients with peripheral arterial disease (PAD) without intermittent claudication

227 d that women with lower extremity peripheral arterial disease (PAD) would have greater mobility loss

228 ystem, but their association with peripheral arterial disease (PAD), a high-prevalence vascular illne

229 ma-based factors as predictors of peripheral arterial disease (PAD), and comparative data between ind

230 risk factors for atherosclerotic peripheral arterial disease (PAD), such as dyslipidemia, diabetes m

231 In participants with peripheral arterial disease (PAD), we determined whether more seden

232 hy for suspected or known chronic peripheral arterial disease (PAD), with contrast material-enhanced

233 nce standard for the diagnosis of peripheral arterial disease (PAD).

234 nd amputation among patients with peripheral arterial disease (PAD).

235 ly performed for the treatment of peripheral arterial disease (PAD).

236 achial index (ABI) and those with peripheral arterial disease (PAD).

237 ality rates in men and women with peripheral arterial disease (PAD).

238 scular mortality in patients with peripheral arterial disease (PAD).

239 osis in patients with concomitant peripheral arterial disease (PAD).

240 sion in subjects with progressive peripheral arterial disease (PAD).

241 66 participants included 412 with peripheral arterial disease (PAD).

242 life in asymptomatic persons with peripheral arterial disease (PAD).

243 a to lower limbs in patients with peripheral arterial disease (PAD).

244 sing avenue for the management of peripheral arterial disease (PAD).

245 ysiological angiogenesis to treat peripheral arterial diseases (PAD) by increasing the vascular endot

246 e impact of polyvascular disease (peripheral arterial disease [PAD] and cerebrovascular disease [CVD]

247 The study population included 203 peripheral arterial disease participants who underwent vertical acc

248 Peripheral arterial disease patients included those with intermitte

249 In femoropopliteal arterial disease, PCB therapy is associated with superio

250 important for the large number of peripheral arterial disease persons without access to supervised wa

251 ery disease, limb ischemia due to peripheral arterial disease, pressure-overload heart failure, wound

252 In spline regression models, peripheral arterial disease prevalence decreased with increasing se

253 Peripheral arterial disease prevalence ranged from 3.1% to 24% of a

254 including hypertension, diabetes, peripheral arterial disease, previous myocardial infarction, angina

255 mellitus, hypertension, smoking, peripheral arterial disease, previous stroke, previous coronary byp

256 Atherosclerosis is an arterial disease process characterized by the focal sube

257 This arterial disease process impairs the supply of oxygen an

258 ween adiposity, metabolic abnormalities, and arterial disease progression in children and adolescents

259 linical CVD but with asymptomatic peripheral arterial disease, regardless of its low CVD risk.

260 re patients who underwent a major peripheral arterial disease-related amputation during the period be

261 scular care and regional rates of peripheral arterial disease-related amputation.

262 on, the most common of which were peripheral arterial disease (reported in 992 [16.2%] of 6137 patien

263 Peripheral Arterial Disease Research Coalition (Europe).

264 Atherosclerosis in the form of peripheral arterial disease results in significant morbidity.

265 y treatment for patients with infrapopliteal arterial disease reveal suboptimal procedural and 1-year

266 , atrial fibrillation, aortic and peripheral arterial disease, rheumatic heart disease, and endocardi

267 ascular risk score (Second Manifestations of Arterial Disease risk score) (RR, 1.01; 95% CI: 1.00, 1.

268 tions to prevent mobility loss in peripheral arterial disease should focus on reversing pathophysiolo

269 alth (REACH) and Secondary Manifestations of Arterial Disease (SMART) risk scores (area under the cur

270 ic obstructive pulmonary disease, peripheral arterial disease, smoking, diabetes, renal failure, hype

271 96%; LR, 3.1 [95% CI, 2.0-4.7]), peripheral arterial disease (specificity, 97%; LR, 2.7 [95% CI, 1.5

272 o-option" patients suffering from peripheral arterial diseases, such as critical limb ischemia (CLI).

273 cal limb ischemia have severe below-the-knee arterial disease that limits the use of bypass surgery o

274 uscular dysplasia (FMD) is a noninflammatory arterial disease that predominantly affects women.

275 of non-atherosclerotic and non-inflammatory arterial diseases that primarily involves the renal and

276 prior coronary artery disease or peripheral arterial disease the COMPASS (Cardiovascular Outcomes fo

277 surgical therapy for coronary and peripheral arterial disease, the burden of these illnesses remains

278 m reviewed the natural history of peripheral arterial disease, the use of paclitaxel in peripheral ar

279 ended for secondary prevention in peripheral arterial disease, their effectiveness in CLI is uncertai

280 valent condition for coronary and peripheral arterial diseases, these findings create a paradox where

281 res is increased in patients with peripheral arterial disease, thus increasing the incidence of repor

282 l infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or

283 hundred seventy participants with peripheral arterial disease underwent baseline measurement of calf

284 Any fractures, peripheral arterial disease, venous thromboembolism, cardiac-relate

285 Peripheral arterial disease was defined as an ankle-brachial blood

286 nium levels and the prevalence of peripheral arterial disease was not statistically significant, alth

287 tive tobacco use, and other risk factors for arterial disease were analyzed by using a multivariate C

288 dy, 141 patients with symptomatic peripheral arterial disease were assigned to treatment with heparin

289 coronary artery bypass graft, and peripheral arterial disease were associated with prescription of as

290 bstructive pulmonary disease, and peripheral arterial disease were less likely to improve (P<0.05 for

291 ial, 76 patients with symptomatic peripheral arterial disease were randomized 2:1 to receive a helica

292 cular ejection fraction <20%, and peripheral arterial disease were significant predictors of mortalit

293 ptions for diabetic patients with peripheral arterial disease when revascularization is not possible

294 ngina, myocardial infarction, and peripheral arterial disease, whereas raised diastolic blood pressur

295 ronic coronary, intracranial, and peripheral arterial diseases, which together account for the leadin

296 hospitalizations of patients with peripheral arterial disease who had peripheral arterial revasculari

297 More than 1 in 6 patients with peripheral arterial disease who undergo peripheral arterial revascu

298 rial in symptomatic patients with peripheral arterial disease who underwent endovascular treatment fo

299 hospitalizations of patients with peripheral arterial disease who were discharged alive after periphe

300 e traditional focus of immunopathogenesis of arterial disease, with the goal of integrating the playe